Your browser doesn't support javascript.
loading
Late dental and bone alterations in patients after orbital rhabdomyosarcoma treatment.
de Mattos, Valkiria D Aiuto; Ferman, Sima Esther; Magalhães, Denise Maria Araújo; da Costa, Felipe Vieira; Antunes, Héliton Spíndola; Junior, Arley Silva.
Afiliação
  • de Mattos VDA; Pediatric Oncology Division, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Ferman SE; Pediatric Oncology Division, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Magalhães DMA; Radiation Oncology Division, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Rio de Janeiro, Brazil.
  • da Costa FV; Private Practice and Pathology Department, Universidade Federal Fluminense (UFF), Niterói, Rio de Janeiro, Brazil.
  • Antunes HS; Clinical Research Division, Instituto Nacional de Câncer (INCA), Rua André Cavalcante, N° 37, 2° Andar, Rio de Janeiro, RJ, CEP-20231-050, Brazil. hspindola@inca.gov.br.
  • Junior AS; Pathology Department, Universidade Federal Fluminense (UFF), Niterói, Rio de Janeiro, Brazil.
Support Care Cancer ; 32(10): 642, 2024 Sep 07.
Article em En | MEDLINE | ID: mdl-39243302
ABSTRACT

PURPOSE:

Orbital rhabdomyosarcoma is a rare soft tissue sarcoma in childhood but with a good prognosis. Treatment usually includes surgery, chemotherapy, and radiotherapy. This study aimed to evaluate long-term alterations in teeth and cranial bones in children, adolescents, and young adults after oncologic treatment for childhood orbital rhabdomyosarcoma.

METHOD:

This was a cross-sectional study that evaluated patients treated for orbital rhabdomyosarcoma between 1988 and 2011. Demographic, clinical, and treatment data were collected during the study period; also, panoramic radiographs, cephalometric study, and photographs of the face were taken.

RESULTS:

Eight long-term survivors were studied. Of those, 50% were male, 75% had less than 5 years of treatment, and 88% had only one of the orbits affected by the tumor. Regarding treatment, 50% received 50.4 Gy of radiotherapy in the orbit; the chemotherapy included vincristine, actinomycin D, and cyclophosphamide in 75% of the cases and also ifosfamide and etoposide in 25%. The children presented craniofacial alterations, mainly when radiotherapy occurred between 0 and 5 years old (p = 0.01). The mandibles also showed dental alterations, probably due to chemotherapy.

CONCLUSION:

In conclusion, orbital RMS patients treated with chemoradiotherapy, important dental, and facial bone alterations were found. The most significant were in the maxilla and close to the irradiation field. Dental and mandibular bone alterations were also found, indicating the probable chemotherapy action, as this region was not included in the irradiation field.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rabdomiossarcoma / Neoplasias Orbitárias Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Support Care Cancer Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rabdomiossarcoma / Neoplasias Orbitárias Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Support Care Cancer Ano de publicação: 2024 Tipo de documento: Article